Piperazine derivatives with ccr1 receptor antagonist activity

Details Piperazine derivatives with ccr1 receptor antagonist activity Piperazine derivatives with ccr1 receptor antagonist activity

C - Chemistry, Metallurgy

07

D

C07D 241/04 (2006.01) A61K 31/495 (2006.01) A61P 29/00 (2006.01) C07D 207/16 (2006.01) C07D 213/63 (2006.01) C07D 213/64 (2006.01) C07D 213/74 (2006.01) C07D 213/75 (2006.01) C07D 213/76 (2006.01) C07D 213/79 (2006.01) C07D 213/80 (2006.01) C07D 213/82 (2006.01) C07D 239/34 (2006.01) C07D 239/60 (2006.01) C07D 257/04 (2006.01) C07D 277/56 (2006.01) C07D 295/185 (2006.01) C07D 307/33 (2006.01) C07D 307/68 (2006.01) C07D 333/38 (2006.01) C07D 401/12 (2006.01)

Patent

CA 2463272

The present invention relates to compounds of the formula (1)and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c. d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the 15 CCR1 receptor in a mammal.

L'invention concerne des composés représentés par la formule (1) et des formes de ceux-ci pharmaceutiquement acceptables. Dans cette formule, X, Y, a, b, c. d, R?1¿, R?2¿, R?3¿, R?4¿ et R?5¿ sont tels que définis dans revendications. L'invention concerne également des compositions pharmaceutiques comprenant un composé représenté par la formule (I) et un excipient pharmaceutiquement acceptable. L'invention concerne enfin des méthodes d'utilisation des composés et compositions précités pour traiter ou prévenir un trouble ou un état par production d'effets antagonistes du récepteur 15 CCR1 chez un mammifère.

Affiliated with

Also associated with

Rating

Piperazine derivatives with ccr1 receptor antagonist activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazine derivatives with ccr1 receptor antagonist activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives with ccr1 receptor antagonist activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1561300